Saturday, July 11, 2026

Patent intelligence · US

US 8435993

Methods of inhibiting metastasis from cancer

granted A61KA61K31/451A61K31/453A61K31/7088
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 7
Applicant portfolio 706
Patent details — US 8435993
Jurisdiction
US
Status
granted
Grant date
May 7, 2013
Expiration
May 2, 2033
Claims
2
CPC classes
A61K, A61K31/451, A61K31/453, A61K31/7088
View on Google Patents ↗

Quick answer

US 8435993 (Methods of inhibiting metastasis from cancer) is held by Alliance Discovery, Inc.. Status: granted. Granted May 7, 2013. Expires May 2, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
2
CPC classes
A61K, A61K31/451, A61K31/453, A61K31/7088, A61K39/3955, A61P

More from Alliance Discovery, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12427173

    Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies

    Biomed Valley Discoveries, Inc. · Expires Sep 25, 2045

    granted
  2. US 12428415

    Matriptase 2 inhibitors and uses thereof

    Disc Medicine, Inc. · Expires Sep 25, 2045

    granted
  3. US 12421236

    Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor

    Medshine Discovery Inc. · Expires Sep 18, 2045

    granted
  4. US 12420085

    Synergistic therapies for inter vertebral disc degeneration

    Discure Technologies Ltd · Expires Sep 18, 2045

    granted
  5. US 12421231

    Azaindole derivatives and their use as ERK kinase inhibitors

    AGV Discovery · Expires Sep 18, 2045

    granted
  6. US 12403069

    Adapter for use in a planetary mixer

    MEDISCA PHARMACEUTIQUE INC. · Expires Aug 28, 2045

    granted
  7. US 12398179

    Nanomolar peptides and derivatives to differentially modulate ephrin receptors

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Expires Aug 21, 2045

    granted
  8. US 12396924

    Adapter for use in a planetary mixer

    MEDISCA PHARMACEUTIQUE INC. · Expires Aug 21, 2045

    granted

Frequently asked questions

What is US patent 8435993?

US 8435993 (Methods of inhibiting metastasis from cancer) is held by Alliance Discovery, Inc.. Status: granted. Granted May 7, 2013. Expires May 2, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8435993?

Alliance Discovery, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.

When does US 8435993 expire?

Our index shows an expiration date of May 2, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.